Statement: Zantac (Ranitidine) Litigation – Delaware Supreme Court to Review Superior Court's Daubert Decision
Statement: Zantac (Ranitidine) Litigation – Delaware Supreme Court to Review Superior Court's Daubert Decision
GSK plc (LSE/NYSE: GSK) welcomes today's decision by the Delaware Supreme Court that it will review the Delaware Superior Court's decision allowing the introduction of plaintiffs' expert evidence at trial. Interlocutory reviews are granted in exceptional circumstances, and GSK is pleased that the Supreme Court is of the view that such circumstances are present here.
GSk plc (LSE/NYSE: GSK)對特拉華州最高法院決定複審特拉華州高級法院允許在審判中引入原告專家證據的決定表示歡迎。特例情況下才會批准中間上訴,GSk很高興看到最高法院認爲此處存在這樣的情況。
The scientific consensus remains that there is no consistent or reliable evidence that ranitidine increases the risk of any cancer. Since 2019, there are 16 epidemiological studies looking at human data regarding the use of ranitidine, including outcomes for more than 1 million patients using ranitidine, supporting this consensus.
科學共識仍然是:沒有一致的或可靠的證據表明雷尼替丁增加了任何癌症的風險。自2019年以來,已經有16項流行病學研究關注使用雷尼替丁的人類數據,包括超過100萬使用雷尼替丁的患者的結果,支持這一共識。
GSK is committed to vigorously defending itself and managing this litigation in the best interests of the Company and its shareholders. The Delaware litigation will progress in parallel with the Delaware Supreme Court review. Alongside review by the Delaware Supreme Court, the Company will press additional defenses in the litigation, including failure to provide proof of use and proof of diagnosis requirements recently ordered by the Court.
GSk致力於積極捍衛自己,並在公司和股東的最佳利益下管理此訴訟。特拉華州的訴訟將與特拉華州最高法院審查同時進行。除了特拉華州最高法院的審查外,公司還將在訴訟中提出其他辯護措施,包括法院最近下令提供使用證明和診斷證明的要求。
Notes to Editors
愛立信的5G網絡基礎設施產品組合包括
* The Daubert standard, established in the U.S. Supreme Court case Daubert v. Merrell Dow Pharmaceuticals, Inc. 509 US 579 (1993) provides criteria for evaluating whether expert testimony is admissible under Federal Rule of Evidence 702. Under Rule 702 and Daubert, an expert may offer testimony if he or she is qualified by knowledge, education, training or experience in a given area and the testimony offered is reliable, relevant and helpful to the jury. In applying the Daubert standard, the Court acts as a gatekeeper, ensuring that expert opinions meet certain standards for reliability and that speculative or unreliable opinions are not presented to the jury. In Daubert, the Supreme Court identified four factors to guide assessment of an expert's methodology: (1) whether the expert's methodology has been tested or is capable of being tested; (2) whether the theory or technique used by the expert has been subjected to peer review and publication; (3) whether there is a known or potential error rate of the methodology; and (4) whether the technique has been generally accepted in the relevant scientific community. The Daubert standard is applicable to expert testimony in all federal cases. Many states also have adopted standards identical to the federal Daubert standard.
* Daubert標準是由美國最高法院案例Daubert v. Merrell Dow Pharmaceuticals, Inc. 509 US 579 (1993)確立的,它爲評估專家證詞是否符合聯邦證據規則702的要求提供了標準。根據規則702和Daubert標準,只有具備在某一特定領域的知識、教育、培訓或經驗的專家可以提供證詞,並且提供的證詞必須是可靠的、相關的且對陪審團有幫助的。在應用Daubert標準時,法院充當守門人的角色,確保專家意見符合某些可靠性標準,並且不會向陪審團呈現投機或不可靠的意見。在Daubert案中,最高法院確定了指導評估專家方法的四個因素:(1)專家方法是否經過測試或可進行測試;(2)專家使用的理論或技術是否經過同行評議和發表;(3)方法的已知或潛在錯誤率是否存在;和(4)該技術是否在相關科學社區中被普遍接受。 Daubert標準適用於所有聯邦案件中的專家證詞。許多州還採用了與聯邦Daubert標準相同的標準。
The term "Daubert Standard" comes from the United States Supreme Court case: Daubert v Merrell Dow Pharmaceuticals Inc 509 US 579 (1993).
道貝特標準一詞來自於美國最高法院的案件:道貝特訴梅瑞爾多公司509美國579(1993)。
About GSK
關於GSK
GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at gsk.com.
GSK是一家全球生物醫藥公司,其目的是通過聯合科學、技術和才華於疾病之前獲得優勢。詳情請訪問gsk.com。
Cautionary statement regarding forward-looking statements
關於前瞻性聲明的警告聲明
GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described under Item 3.D "Risk factors" in GSK's Annual Report on Form 20-F for 2023, and GSK's Q2 Results for 2024.
GSk 提示投資者,GSk 在本公告中發表的任何前瞻性聲明或預測都存在風險和不確定性,可能導致實際結果與預期結果有所不同。 這些因素包括但不限於 GSK 的 2023 年年度報告表格 20-F 的第 3.D 條「風險因素」和 2024 年第二季度業績。